id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-P-0381-0005,FDA,FDA-2005-P-0381,"Attachment 2 - Product Description for Diphenoxylate Hydrochloride and Atropin Sulfate Tablets and Oral Solution, 5 mg/0.05 mg re Citizens Petition from Lachman Consultant Services, Inc.",Supporting & Related Material,Background Material,2008-12-30T05:00:00Z,2008,12,,,2024-11-12T17:56:32Z,,0,0,09000064807ddd58
FDA-2005-P-0381-0004,FDA,FDA-2005-P-0381,"Petition Denial from FDA CDER to Lachman Consultant Services, Inc.",Other,PDN-Petition Denial,2008-12-24T05:00:00Z,2008,12,2008-12-24T05:00:00Z,,2024-11-12T17:54:02Z,,0,0,09000064807dcb48
FDA-2005-P-0381-0003,FDA,FDA-2005-P-0381,"Citizens Petition from Lachman Consultant Services, Inc.",Other,CP-Citizen Petition,2008-12-24T05:00:00Z,2008,12,2008-12-24T05:00:00Z,,2024-11-12T17:52:49Z,,0,0,090000648044bec6
FDA-2005-P-0381-0002,FDA,FDA-2005-P-0381,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc.",Other,Acknowledgement Letter/Receipt,2005-04-26T04:00:00Z,2005,4,,,2024-11-12T17:50:33Z,,0,0,090000648044bed9
FDA-2005-P-0381-0001,FDA,FDA-2005-P-0381,"Acknowledgement Letter from FDA DDM to Lachman Consultant Services, Inc.",Other,Acknowledgement Letter/Receipt,2005-04-26T04:00:00Z,2005,4,,,2024-11-12T17:49:28Z,,0,0,090000648044be91